Sexually Transmitted Diseases, Bacterial
14
2
3
9
Key Insights
Highlights
Success Rate
90% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
7.1%
1 terminated out of 14 trials
90.0%
+3.5% vs benchmark
14%
2 trials in Phase 3/4
22%
2 of 9 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 9 completed trials
Clinical Trials (14)
Randomized Directly Observed Therapy Study to Interpret Clinical Trials of Doxy-PEP
Mobile Enhanced Prevention Support for People Leaving Jail
Alignment of PrEP Use With HIV Risk in Young Women and Men
Game Plan: Efficacy of a Brief, Web-based Intervention on Alcohol Use and Sexually-transmitted Infections
Superiority of On-demand PrEP Versus PEP on Using Doxycycline for Preventing STI in MSM
The Antibiotic Guardian Study- Clinical Evaluation of a Novel, Rapid Diagnostic for Gonorrhoea and Mycoplasma Infections.
Same-Day PrEP Initiation and Sexual Health for Transgender Women
Integrating Enhanced HIV PrEP Into a STI Clinic in Lilongwe
Mycoplasma Species and the Genitourinary System
Psychoeduc Interv. Through Meta-universes on Condom's Use Self - Efficacy and Sexual Behavior in Students of UAChile
Evaluation of Presumptive Periodic Treatment (PPT) of Sexually Transmitted Infections (STIs)
Self-taken Penile Meatal Swabs for Chlamydia, Gonorrhoea and Mycoplasma Genitalium Detection
UROGEN WELL D-ONE : Evaluation of a Novel Diagnostic for Sexually Transmitted Bacterial Infections
Evaluation of the Use of the Colli-Pee Device to Collect First-void Urine for Molecular Detection of STIs